[United States Statutes at Large, Volume 132, 115th Congress, 2nd Session]
[From the U.S. Government Publishing Office, www.gpo.gov]


Public Law 115-411
115th Congress

An Act


 
To direct the Administrator of the United States Agency for
International Development to submit to Congress a report on the
development and use of global health innovations in the programs,
projects, and activities of the Agency. <>

Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled, <>
SECTION 1. SHORT TITLE.

This Act may be cited as the ``Global Health Innovation Act of
2017''.
SEC. 2. ANNUAL REPORT.

(a) <>  In General.--Not later than 180 days
after the date of the enactment of this Act, and annually thereafter for
a period of 4 years, the Administrator of the United States Agency for
International Development shall submit to Congress a report on the
development and use of global health innovations in the programs,
projects, and activities of the Agency.

(b) Matters To Be Included.--The report required by subsection (a)
shall include the following:
(1) A description of--
(A) the extent to which global health innovations
described in subsection (a) include drugs, diagnostics,
devices, vaccines, electronic and mobile health
technologies, and related behavior change and service
delivery innovations;
(B) how innovation has advanced the Agency's
commitments to achieving an HIV/AIDS-free generation,
ending preventable child and maternal deaths, and
protecting communities from infectious diseases, as well
as furthered by the Global Health Strategic Framework;
(C) how goals are set for health product development
in relation to the Agency's health-related goals and how
progress and impact are measured towards those goals;
(D) how the Agency's investments in innovation
relate to its stated goals; and
(E) progress made towards health product development
goals.
(2) How the Agency, both independently and with partners,
donors, and public-private partnerships, is--
(A) leveraging United States investments to achieve
greater impact in health innovation;
(B) engaging in activities to develop, advance, and
introduce affordable, available, and appropriate global
health products; and

[[Page 5425]]

(C) scaling up appropriate health innovations in the
development pipeline.
(3) A description of collaboration and coordination with
other Federal departments and agencies, including the Centers
for Disease Control and Prevention, in support of global health
product development, including a description of how the Agency
is working to ensure critical gaps in product development for
global health are being filled.
(4) A description of how the Agency is coordinating and
aligning global health innovation activities between the Global
Development Lab, the Center for Accelerating Innovation and
Impact, and the Bureau for Global Health.

Approved January 3, 2019.

LEGISLATIVE HISTORY--H.R. 1660:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 164 (2018):
Jan. 17, 18, considered and passed House.
Dec. 20, considered and passed Senate.